Skip to main content
OpenTrials
Completed

NCT Number: NCT06148129

Immunohistochemistry Role in Better Prognosis of Endometrial Carcinoma Patients

The incidence of endometrial cancer (EC) is increasing .Different risk classifications are used to direct the primary and adjuvant therapy. The European Society for Medical Oncology - European Society of Gynaecological Oncology -European Society for Radiotherapy & Oncology (ESMO-ESGO- ESTRO) could guide the need for lymph node surgery pre-operatively, and also post-operatively to determine adjuvant treatment.

Low-risk patients are managed with surgery alone, while higher-risk group patients undergo more aggressive surgical options. So, it is important to identify new prognostic markers for better stratification of patients to avoid under- or over treatment of EC patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Endometrial Cancer Endometrial Neoplasms Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Neoplasms Neoplasms by Site Urogenital Diseases Urogenital Neoplasms Uterine Diseases Uterine Neoplasms

Age range

36 year–72 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Zagazig university

Zagazig, Ash Sharqia Governorate, 44519, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • aged 36 -72 years;
  • Previously diagnosed with endometrial carcinoma;
  • Histological Type of the tumor;
  • Myometrial Invasion;
  • lymph Node Invasion;
  • Cervical Invasion;
  • Biomarkers expression.

Exclusion criteria

  • Lack of tumor tissue in tissue block

Treatment and study plan

Tissue Biopsy

Diagnostic Test

The Post-hysterectomy tissue biopsy was analyzed immunohistochemically for detection of estrogen and progesterone receptors, P53 and L1CAM

Primary outcomes

  1. expression levels of p53/L1CAM/ER/PR

    Time frame: 36 Months

    The Prognostic value of immunohistochemical detection of expression levels of p53/L1CAM/ER/PR in relation to ESMO-ESGO-ESTRO risk groups

Sponsors and collaborators

Lead sponsor

Zagazig University

Other Gov

Registry information

Official study title

Stratification of Endometrial Carcinoma Patients Using Immunohistochemistry for Better Surgical Planning and Prognosis

Important dates

Study start
2019
Primary completion
2021
Study completion
2022
First posted
Nov 28, 2023
Registry last updated
Nov 28, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.